Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DNA NASDAQ:HRTX NASDAQ:TECX NASDAQ:ZURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNAGinkgo Bioworks$10.02-4.0%$12.00$5.00▼$16.85$593.18M1.51.58 million shs1.46 million shsHRTXHeron Therapeutics$1.26-1.6%$1.63$1.04▼$2.68$230.98M1.221.44 million shs1.40 million shsTECXTectonic Therapeutic$17.72-1.7%$21.96$13.70▼$61.07$331.54M3.42461,828 shs331,030 shsZURAZura Bio$2.00-1.0%$1.71$0.97▼$5.07$130.04M-0.02318,404 shs255,330 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNAGinkgo Bioworks0.00%-9.85%-23.86%+9.32%+58.54%HRTXHeron Therapeutics0.00%-3.82%-5.26%-37.93%-32.62%TECXTectonic Therapeutic0.00%+5.48%-24.63%-17.77%-1.50%ZURAZura Bio0.00%-9.09%+20.48%+66.67%-45.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNAGinkgo Bioworks$10.02-4.0%$12.00$5.00▼$16.85$593.18M1.51.58 million shs1.46 million shsHRTXHeron Therapeutics$1.26-1.6%$1.63$1.04▼$2.68$230.98M1.221.44 million shs1.40 million shsTECXTectonic Therapeutic$17.72-1.7%$21.96$13.70▼$61.07$331.54M3.42461,828 shs331,030 shsZURAZura Bio$2.00-1.0%$1.71$0.97▼$5.07$130.04M-0.02318,404 shs255,330 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNAGinkgo Bioworks0.00%-9.85%-23.86%+9.32%+58.54%HRTXHeron Therapeutics0.00%-3.82%-5.26%-37.93%-32.62%TECXTectonic Therapeutic0.00%+5.48%-24.63%-17.77%-1.50%ZURAZura Bio0.00%-9.09%+20.48%+66.67%-45.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNAGinkgo Bioworks 2.33Hold$9.50-5.19% DownsideHRTXHeron Therapeutics 2.33Hold$4.50257.14% UpsideTECXTectonic Therapeutic 3.14Buy$80.29353.08% UpsideZURAZura Bio 3.00Buy$14.00600.00% UpsideCurrent Analyst Ratings BreakdownLatest ZURA, HRTX, DNA, and TECX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025TECXTectonic TherapeuticOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$80.008/25/2025DNAGinkgo BioworksBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$6.00 ➝ $9.008/19/2025ZURAZura BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$3.00 ➝ $2.008/15/2025ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$17.00 ➝ $16.008/15/2025ZURAZura BioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/12/2025HRTXHeron TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell8/8/2025DNAGinkgo BioworksCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/8/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $3.007/21/2025TECXTectonic TherapeuticTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$64.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNAGinkgo Bioworks$227.04M2.61N/AN/A$13.17 per share0.76HRTXHeron Therapeutics$149.69M1.54N/AN/A($0.22) per share-5.73TECXTectonic TherapeuticN/AN/AN/AN/A$9.54 per shareN/AZURAZura BioN/AN/AN/AN/A$2.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNAGinkgo Bioworks-$547.03M-$5.86N/AN/AN/A-136.56%-43.25%-22.29%11/11/2025 (Estimated)HRTXHeron Therapeutics-$13.58M-$0.02N/AN/AN/A-0.62%N/A-0.40%11/11/2025 (Estimated)TECXTectonic Therapeutic-$57.98M-$4.04N/AN/AN/AN/A-30.13%-28.33%11/6/2025 (Estimated)ZURAZura Bio-$45.39M-$0.70N/AN/AN/AN/A-49.11%-40.06%11/6/2025 (Estimated)Latest ZURA, HRTX, DNA, and TECX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ZURAZura Bio-$0.19-$0.17+$0.02-$0.17N/AN/A8/8/2025Q2 2025HRTXHeron Therapeutics-$0.01-$0.02-$0.01-$0.02$38.08 million$37.20 million8/7/2025Q2 2025DNAGinkgo Bioworks-$1.44-$1.10+$0.34-$1.10$41.60 million$49.60 million8/7/2025Q2 2025TECXTectonic Therapeutic-$0.98-$1.07-$0.09-$1.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNAGinkgo BioworksN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNAGinkgo BioworksN/A5.415.41HRTXHeron TherapeuticsN/A0.820.53TECXTectonic TherapeuticN/A25.6025.60ZURAZura BioN/A8.408.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNAGinkgo Bioworks78.63%HRTXHeron Therapeutics80.01%TECXTectonic Therapeutic62.63%ZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipDNAGinkgo Bioworks9.72%HRTXHeron Therapeutics5.86%TECXTectonic Therapeutic9.20%ZURAZura Bio22.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNAGinkgo Bioworks64059.20 million53.45 millionOptionableHRTXHeron Therapeutics300183.32 million172.57 millionOptionableTECXTectonic Therapeutic12018.71 million16.99 millionN/AZURAZura Bio365.02 million50.65 millionOptionableZURA, HRTX, DNA, and TECX HeadlinesRecent News About These CompaniesHead to Head Review: Zura Bio (NASDAQ:ZURA) and Genmab A/S (OTCMKTS:GNMSF)3 hours ago | americanbankingnews.comAllostery Investments LP Acquires 714,258 Shares of Zura Bio Limited $ZURASeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Raises Stake in Zura Bio Limited $ZURASeptember 4, 2025 | marketbeat.comZura Bio Unveils Updated Corporate PresentationSeptember 4, 2025 | tipranks.comZura Bio Limited (NASDAQ:ZURA) Receives $14.00 Consensus Price Target from BrokeragesSeptember 4, 2025 | americanbankingnews.comZura Bio Limited (NASDAQ:ZURA) Receives Average Rating of "Buy" from AnalystsSeptember 2, 2025 | marketbeat.comFY2025 EPS Estimates for Zura Bio Boosted by HC WainwrightAugust 23, 2025 | marketbeat.comZura Bio (NASDAQ:ZURA) Given New $2.00 Price Target at HC WainwrightAugust 21, 2025 | marketbeat.comZura Bio price target lowered to $2 from $3 at H.C. WainwrightAugust 19, 2025 | msn.comQ1 Earnings Estimate for Zura Bio Issued By Leerink PartnrsAugust 19, 2025 | marketbeat.comZura Bio (NASDAQ:ZURA) Price Target Cut to $16.00 by Analysts at OppenheimerAugust 17, 2025 | marketbeat.comZura Bio (NASDAQ:ZURA) Earns Buy Rating from Chardan CapitalAugust 17, 2025 | marketbeat.comZura Bio (NASDAQ:ZURA) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPSAugust 16, 2025 | marketbeat.comZura Bio price target lowered to $16 from $17 at OppenheimerAugust 15, 2025 | msn.comZura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate UpdatesAugust 14, 2025 | businesswire.comRobert Lisicki on Living Up to Zura Bio’s Heroic NamesakeJuly 31, 2025 | pharmexec.comP3 Penny Stocks With Market Caps Over $70M Worth WatchingJuly 18, 2025 | finance.yahoo.comZura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 18, 2025 | finance.yahoo.comZura Bio Announces Chief Financial Officer TransitionJuly 1, 2025 | businesswire.comZura Bio shareholders approve board nominees and auditorMay 24, 2025 | investing.comZura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativaMay 21, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZURA, HRTX, DNA, and TECX Company DescriptionsGinkgo Bioworks NYSE:DNA$10.02 -0.42 (-4.02%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$10.26 +0.24 (+2.35%) As of 06:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Heron Therapeutics NASDAQ:HRTX$1.26 -0.02 (-1.56%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.29 +0.03 (+2.38%) As of 06:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Tectonic Therapeutic NASDAQ:TECX$17.72 -0.31 (-1.72%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$17.70 -0.02 (-0.11%) As of 05:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.Zura Bio NASDAQ:ZURA$2.00 -0.02 (-0.99%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.08 +0.08 (+3.80%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
